Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Summary

A phase II, open label, single arm, single agent study using nivolumab in patients who failed 2 or more lines of previous chemotherapy for recurrent/metastatic NPC (At least 1 line should include platinum based chemotherapy)

Timeline

Start

2018-06

Primary completion

2019-05

Completion

2019-06

Outcome

Outcome not reported

Stopped (Business): “Sponsor withdrew funding for Nivolumab”

Drugs

Indications